# DeLLphi-304 (NCT05740566)

> Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05740566
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Small Cell Lung Cancer (SCLC)
- Interventions: Tarlatamab; Lurbinectedin; Topotecan; Amrubicin
- Enrollment: 509
- Primary outcome: Overall Survival (OS)

## Commentary we found

- X threads: 120
- YouTube: 67
- Podcasts: 47
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dellphi-304-nct05740566

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05740566", "email": "<work email>"}; the inbox owner confirms by the emailed link.